NasdaqGS:RPRXPharmaceuticals
Royalty Pharma (RPRX): Assessing Valuation After Bold $4 Billion in New Deals and Funding Moves
Royalty Pharma (RPRX) just made some bold moves that have investors leaning in a little closer. In September, the company completed a $2 billion senior notes offering, giving it more firepower to go after long-term royalty assets and sign new deals. In addition, Royalty Pharma announced a $2 billion synthetic royalty agreement with Revolution Medicines, targeting a late-stage oncology drug. Together, these headline acts signal that Royalty Pharma is betting big on future growth through an...